Bayer Schering Pharma has obtained the rights to distribute insulin in China from Polish biotech Bioton. Bayer paid 31 million euros ($43.5 million) upfront for 15-year rights to Bioton’s insulin, in a deal expected to generate between $1.5 billion and $2 billion of sales over the length of the contract. Analysts opined that Bioton’s margins would be between 20% and 30% on the product. More details...

Stock Symbol: (Xetra: BAYG.DE)